Sugi Predict

Sugi Predict / Compounds / SCHEMBL1933799

SCHEMBL1933799

SCHEMBL1933799

Cc1ccc(S(=O)(=O)n2ccc3c(Cl)c(C=O)cnc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ UBE2N P61088 1/20 0.47
▸ BRD4 O60885 3/20 0.42
▸ PKM P14618 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ ALDH3A1 P30838 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.38
▸ PDE4A P27815 2/20 0.37
▸ PDE4B Q07343 2/20 0.37
▸ PDE4C Q08493 2/20 0.37
▸ PDE4D Q08499 2/20 0.37
▸ RAPGEF4 Q8WZA2 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ PTPN11 Q06124 1/20 0.36
▸ GRM4 Q14833 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18855917 0.89 L3MBTL1 (0.46) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL29817507 0.88 CYP2C19 (0.46) PKMCYP2C19HTTMEN1KMT2A
SCHEMBL1134990 0.88 CYP2C19 (0.46) PKMCYP2C19HTTMEN1KMT2A
SCHEMBL28594637 0.85 L3MBTL1 (0.43) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL12035853 0.85 L3MBTL1 (0.43) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL1356064 0.85 L3MBTL1 (0.51) L3MBTL1BRD4PKMPOLBALDH3A1
SCHEMBL16052697 0.85 L3MBTL1 (0.51) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL30509477 0.85 L3MBTL1 (0.51) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL12555251 0.82 L3MBTL1 (0.41) L3MBTL1KDM4EUBE2NBRD4PKM
SCHEMBL20535940 0.82 L3MBTL1 (0.49) L3MBTL1BRD4PKMPOLBALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2025-02-27 — — US disclosed
EP-4444420-A2 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 — — EP disclosed
US-11826365-B2 Type II raf kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-28 — — US disclosed
US-11826365-B2 Type II raf kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-28 — — US disclosed
WO-2023107723-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 — — EP disclosed
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 — — EP disclosed
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2021-03-04 — — US disclosed
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2021-03-04 — — US disclosed
US-20200297721-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-24 — — US disclosed
EP-2519517-A2 TYPE II RAF KINASE INHIBITORS Dana-Farber Cancer Institute, Inc. (US) 2012-11-07 — — EP disclosed
EP-2506716-A1 NOVEL TRICYCLIC COMPOUNDS Abbott Laboratories (US) 2012-10-10 — — EP disclosed
CN-102711476-A Novel tricyclic compounds ABBOTT LAB 2012-10-03 — — CN disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
WO-2011090738-A2 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-07-28 — — WO disclosed
WO-2011090738-A2 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-07-28 — — WO disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826365-B2 Type II raf kinase inhibitors BRAF, RAF1, ARAF L3MBTL1 1340/4885KDM4E 2466/4885UBE2N 2468/4885
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885KDM4E 4131/4885UBE2N 2967/4885
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DYRK2, DYRK1A, PYGB L3MBTL1 3340/4885KDM4E 1748/4885UBE2N 2730/4885
US-20200297721-A1 TYPE II RAF KINASE INHIBITORS BRAF, RAF1, ARAF L3MBTL1 1340/4885KDM4E 2466/4885UBE2N 2468/4885
US-20110311474-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885KDM4E 4131/4885UBE2N 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.